The agency gave approval for the treatment Provenge on Thursday.
The Food and Drug Administration approved a unique treatment for prostate cancer on Thursday. As reported by the Associated Press (AP), the therapy Provenge, a vaccine that treats prostate cancer, is stated to be the first of its type to gain FDA approval.
Dr. Phil Kantoff, an oncologist at the Dana-Farber Cancer Institute who assisted with studies related to the therapy, is quoted by the AP as stating of it gaining approval, “The big news here is that this is the first immunotherapy to win approval, and I suspect within five to ten years immunotherapies will be a big part of cancer therapy in general.”
As noted in the report, Provenge provides an alternative to treatments such as chemotherapy that helps facilitate use of the body’s natural defense system in fighting the disease.